viewAvacta Group PLC

Avacta raises £9mln as its moves towards first clinical trial

Seven evaluations are ongoing with possible partners, which includes four out of the top ten global diagnostics companies.

Avacta Group PLC -
AVA004 is being paused in favour of Pro-Doxorubicin

Biotech firm Avacta Group PLC (LON:AVCT) is to raise £9mln to push ahead with a first clinical trial of anti-cancer treatment Pro-Doxorubicin.

Avacta will use the funds to accelerate the collaboration with Tufts University Medical School on the drug, which is a new form of standard cancer drug Doxorubicin.

WATCH: Avacta Group PLC boss sees a huge opportunity with new version of cancer treatment

Doxorubicin has been a standard of care for soft tissue sarcomas for 40 years, but its use is limited by the heart damage it causes. Even so, the drug still generates US$1bn a year in revenues.

AVA6000, the combination with the technology licensed from Tufts last year is inert until activated by a tumour, which reduces the heart’s exposure to the chemotherapy and concentrates the active drug in the tumour.

Testing of ‘AVA6000 Pro-Doxorubicin’ has been limited to mice so far, but Avacta plans to start dosing patients in a phase 1 clinical trial in the second quarter of 2020, pending application and regulatory approval.

Avacta had previously said its first drug into human trials would be an Affimer PD-L1 inhibitor cancer treatment known as AVA004, but has decided to focus on Pro-Doxorubicin because it provides an opportunity for major licensing deal much sooner.

The £9mln of new money is being raised through a placing at 15p though there is also a small subscription.

Alastair Smith, chief executive, said that it was an “exciting time on all fronts” for the group and not just Pro-Doxorubicin.

Seven evaluations are ongoing with possible partners, he said, which includes four out of the top ten global diagnostics companies.

Heavier research spending meant a loss before tax of £11.1mln, in the year to July.

Gross profits though jumped 72% to £3.2mln, which included US$2.5mln received from new partner LG Chem Life Sciences.

Last December, LG Chem, a Korean group, agreed to fund development and eventually license Affimer technology in a deal potentially worth over US$300mln.

Quick facts: Avacta Group PLC

Price: 168 GBX

Market: AIM
Market Cap: £350.78 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Mkango Resources' Will Dawes welcomes launch of innovative rare earth...

Mkango Resources Ltd's (LON:MKA)(CVE:MKA) Will Dawes caught up with Proactive's Andrew Scott following the launch of its Innovate UK grant-funded project "Rare-Earth Recycling for E-Machines" (RaRE). Dawes adds they've been continuing work on the feasibility study at Songwe Hill with...

39 minutes ago

2 min read